Physician profile
Khalid R Butt
NPI 1982676060
$2,840.65
in general payments reported to CMS, 2019-2025
23 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $433 · 2021: $540 · 2022: $584 · 2023: $458 · 2024: $87.15 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $580.10 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $341.92 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $290.61 | 2019-2025 | |
| Novo Nordisk INC | $268.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $215.03 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.35 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $175.72 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $168.14 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $96.86 | 2019-2021 | |
| Allergan, INC. | $78.64 | 2019-2020 | |
| Amarin Pharma, INC. | $62.32 | 2020-2021 | |
| Lilly USA, LLC | $48.77 | 2019-2025 | Mounjaro |
| Abbvie INC. | $43.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $40.54 | 2021-2023 | |
| Abbott Laboratories | $38.73 | 2021-2023 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $35.69 | 2025 | Sublocade |
| Astellas Pharma US INC | $32.76 | 2022 | |
| Exact Sciences Corporation | $32.36 | 2023 | Cologuard Collection Kit |
| Corium, LLC | $24.83 | 2022 | |
| Grifols USA, LLC | $21.95 | 2021 | |
| Braeburn INC. | $20.35 | 2025 | Brixadi |
| Phathom Pharmaceuticals, INC. | $17.41 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.